Regenicin, Inc. (RGIN)

Market Cap	153.00 -100.0%
Revenue (ttm)	n/a
Net Income	-985.39K
EPS	-0.01
Shares Out	153.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,000
Average Volume	57,199
Open	0.0000
Previous Close	n/a
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.7501
Beta	-46.21
RSI	44.54
Earnings Date	n/a

About Regenicin

Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGIN